Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 15247 in total
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Approved
Experimental
Matched Categories: … Hypnotics and Sedatives ... Herbs and Natural Products …
Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can...
Approved
Investigational
Matched Description: … muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and ... [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under …
Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.
Approved
Vet approved
Matched Description: … Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and
Matched Categories: … Alimentary Tract and Metabolism ... Antiseptics and Disinfectants ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Matched Description: … An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. …
Matched Categories: … Ergot Alkaloids and Derivatives …
Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Iupac: … 3E,3'R)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene]methyl}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Matched Description: … infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative ... was subsequently approved in the United States with additional indications for skin and skin structure …
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Approved
Investigational
Withdrawn
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … B domain replaced with a twenty-four amino acid linker. ... These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for …
Matched Categories: … Blood and Blood Forming Organs …
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Approved
Investigational
Matched Iupac: … -[(1Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Approved
Investigational
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Approved
Vet approved
Matched Categories: … trichlormethiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... trichlormethiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence...
Approved
Vet approved
Matched Description: … Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin ... Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and ... It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs …
Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine....
Approved
Vet approved
Matched Description: … Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals ... Therapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is ... nucleophilic attack is facilitated by the catalytic triad consisting of histidine-57, aspartate-102, and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Preparations for Treatment of Wounds and Ulcers …
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic...
Approved
Investigational
Matched Description: … It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription ... risk for metastases and death [A31846]. ... Apalutamide displayed good tolerability and safety profile in clinical studies. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like morphine and oxycodone. Fentanyl's high potency has also...
Approved
Illicit
Investigational
Vet approved
Matched Description: … Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia ... Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and
Matched Categories: … Fentanyl and fentanyl analogues …
Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional...
Approved
Matched Description: … known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and ... This effect may help to improve memory/judgment, improve walking ability, and support the healing of ... selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and
Matched Categories: … Genito Urinary System and Sex Hormones …
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus ... Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and ... other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does...
Approved
Investigational
Matched Description: … , such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. ... Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. ... receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and
Matched Categories: … Miscellaneous Anxiolytics Sedatives and Hypnotics …
Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy ... Preparations for Treatment of Wounds and Ulcers …
Displaying drugs 676 - 700 of 15247 in total